ARTICLE | Company News

AbbVie sales and marketing update

January 26, 2015 8:00 AM UTC

AbbVie entered an agreement with the ADAP Crisis Task Force (ACTF) to provide its HCV regimen Viekira Pak at an undisclosed discount to state AIDS Drug Assistance Programs (ADAPs). In December, FDA approved Viekira Pak with or without ribavirin to treat HCV genotype 1 infection in patients with and without compensated cirrhosis, including those co-infected with HIV. AbbVie set the wholesale acquisition cost (WAC) for the three direct-acting-antiviral (3-DAA) treatment regimen at $83,319 for a 12-week course.

ADAPs provide HIV treatments to low-income, uninsured and underinsured individuals with HIV infection. The ACTF, formed by state AIDS and ADAP directors and the National Alliance of State & Territorial AIDS Directors (NASTAD), estimates that up to 30% of individuals with HIV infection are co-infected with HCV. ...